Six years after the SEC’s case against Barry Honig, newly released court transcripts are reshaping the story. What once appeared to be a clear example of investor misconduct now shows that David Hansen, a key SEC cooperator and former MabVax Therapeutics CEO, may have misled regulators about Honig’s role. Hansen had received more than $40...